Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 6/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236526 | 0.98 | KMT2A (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL6249941 | 0.98 | KMT2A (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL6249937 | 0.98 | KMT2A (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL236527 | 0.98 | KMT2A (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL3340721 | 0.97 | KMT2A (0.57) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL935547 | 0.97 | KMT2A (0.57) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| Phenylacetic Acid SCHEMBL6567966 | 0.94 | KMT2A (0.54) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL31499163 | 0.94 | NAALAD2 (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| Glycine SCHEMBL28484996 | 0.93 | KMT2A (0.53) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL20302075 | 0.90 | KMT2A (0.50) | KMT2ACNR2NAALAD2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119947713-A | Composition for accurate cancer treatment and accurate cancer treatment method | 斯坦尼斯瓦夫·R·布尔津斯基 | 2025-05-06 | — | — | CN | claimed |
| EP-0680756-B1 | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis | BURZYNSKI STANISLAW R (US) | 1999-08-18 | — | — | EP | claimed |
| US-5646182-A | Methods for treating autoimmune diseases | BURZYNSKI STANISLAW R (US) | 1997-07-08 | — | — | US | claimed |
| EP-0680756-A1 | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis | BURZYNSKI, Stanislaw R. (US) | 1995-11-08 | — | — | EP | claimed |
| US-5391575-A | Method for treating neurofibromatosis | BURZYNSKI STANISLAW R (US) | 1995-02-21 | — | — | US | claimed |
| EP-0603383-A4 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES. | BURZYNSKI STANISLAW R (US) | 1994-12-21 | — | — | EP | claimed |
| EP-0601164-A4 | METHODS FOR TREATING VIRAL INFECTIONS. | BURZYNSKI STANISLAW R (US) | 1994-10-26 | — | — | EP | claimed |
| EP-0603383-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES | BURZYNSKI, Stanislaw R. (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0601164-A1 | METHODS FOR TREATING VIRAL INFECTIONS | BURZYNSKI, Stanislaw R. (US) | 1994-06-15 | — | — | EP | claimed |
| WO-1993025201-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES | BURZYNSKI STANISLAW R (US) | 1993-12-23 | — | — | WO | claimed |
| WO-1993024123-A1 | METHODS FOR TREATING VIRAL INFECTIONS | BURZYNSKI STANISLAW R (US) | 1993-12-09 | — | — | WO | claimed |
| US-5244922-A | Methods for treating viral infections | BURZYNSKI STANISLAW R (US) | 1993-09-14 | — | — | US | claimed |
| CN-119947713-A | Composition for accurate cancer treatment and accurate cancer treatment method | 斯坦尼斯瓦夫·R·布尔津斯基 | 2025-05-06 | — | — | CN | disclosed |
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | CIBA CORPORATION (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2120846-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008107347-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-5254587-A | Methods for treating AIDS | BURZYNSKI STANISLAW R (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0500905-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS. | BURZYNSKI STANISLAW R (US) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992004027-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS | BURZYNSKI STANISLAW R (US) | 1992-03-19 | — | — | WO | disclosed |
| US-5089508-A | METHODS FOR TREATING AIDS | BURZYNSKI STANISLAW R (US) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | MAOA, MAOB, ACMSD | KMT2A 1439/4885CNR2 1773/4885NAALAD2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.